Ildong Pharmaceutical's Postbiotics raw material listed in the US FDA NDI

Obtaining advantageous requirement for commercialization by being recognized for safety

Utilized as a raw material for 'gQlab Postbiotics RHT'

  Ildong Pharmaceutical (CEO Paul Woongsup Yun) has received NDI (New Dietary Ingredient) approval from the US FDA for its postbiotics raw material 'RHT3201'.

  NDI approval is a procedure in which FDA reviews the information of the relevant ingredients to confirm the safety of functional raw material. Because it is strictly managed, only about 15% of the total number of applications passes the procedure.

  Ildong Pharmaceutical's RHT3201 is 'postbiotics', which means metabolites produced by probiotics, and is a material obtained by the heat-treated 'Lactobacillus rhamnosus IDCC3201', a strain independently developed by Ildong Pharmaceutical.

  In particular, the effectiveness related to skin immunity was proved through clinical test conducted by Ajou University Hospital, and it was the first domestic postbiotics to be recognized for its individually-recognized functionality by the Ministry of Food and Drug Safety.

An official from Ildong Pharmaceutical said, "In addition to the functionality of RHT3201, we have secured safety through FDA NDI approval."

  Also, the official said, “When entering the domestic and overseas markets, we have not only secured public confidence in raw materials and finished products, but also shortened the time and the procedures required for registration”.

  Currently, RHT3201 is being used in Ildong Pharmaceutical's "gQlab Postbiotics RHT," a health functional food helpful for intestinal health and skin immunity.

  Ildong Pharmaceutical plans to develop and commercialize RHT3201 into raw materials, finished products, and medical materials by continuously pursuing various research and development.